Skip to content

Author

Moataz A. Shaldam

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Tailored [1,2,4]triazolo[1,5-a]pyrimidine hybrids as promising anti-inflammatory agents with COX/5-LOX/ROS/IL-6 multifunctional inhibitory activity: design, synthesis, SAR, and in silico study

To develop potent anti-inflammatory agents with safer profiles, a hybridization approach combining [1,2,4]triazolo[1,5-a]pyrimidine/chalcone (5a–g) and [1,2,4]triazolo[1,5-a]pyrimidine/pyrazole (6a–g) has been rationally designed to synthesize potential COX/5-LOX/ROS/IL-6 multifunctional inhibitors. All synthesized hyb...

Esraa Elazony, Nermine A. Osman, Moataz A. Shaldam et al. · 0 citations
Open access Sep 2026

Design and synthesis of 1,3,4-oxadiazole-tethered N-substituted isatin hybrids as SARS-CoV-2 main protease inhibitors: biological evaluation, kinetic investigation, and in silico studies

The ongoing emergence of SARS-CoV-2 mutations underscores the urgent need for new antivirals that target key viral proteins. This study describes the design, synthesis, and evaluation of two series of 1,3,4-oxadiazole-tethered N-substituted isatin hybrids as inhibitors of the SARS-CoV-2 main protease (Mpro): 1,2,3-tria...

T. Al-Warhi, Md Sofequl Islam Mukim, Zainab M. Elsayed et al. · 1 citation
Review Sep 2026

Mutant isocitrate dehydrogenase in cancer: Structural biology, small-molecule inhibitors, and future drug discovery strategies.

This review classifies mutant IDH inhibitors by chemical scaffold and relates their binding in the allosteric pocket to structure-activity trends, isoform selectivity, brain penetration, and clinical outcome.

Moataz A. Shaldam, Anwar A. El-Hamaky, Nourhan A. Khattab et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.